Posted by Michael Wonder on 11 Oct 2021
Health economic assessment of Poteligeo in the treatment of mycosis fungoides or Sézary syndrome
11 October 2021 - TLV has produced a health economic assessment for the regions for the drug Poteligeo (mogamulizumab).
The evaluation concerns the treatment of adult patients with so-called mycosis fungoides or Sézary syndrome who have received at least one previous systemic treatment. Systemic treatment is a treatment that is taken by mouth or by injection.
